<DOC>
	<DOC>NCT00167661</DOC>
	<brief_summary>The purpose of this study is to determine whether Campath-1H induction and the associated lymphocyte depletion will permit long-term rejection-free renal allograft survival in the absence of ongoing corticosteroid administration.</brief_summary>
	<brief_title>Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>1. Male or female subjects, aged 18 months 18 years inclusive. 2. Subjects must be a singleorgan recipient (kidney only). 3. Subjects who are receiving their first living donor or deceased donor transplant. 1. Subjects who are recipients of HLAidentical livingdonor renal transplants. 2. Subjects with a PRA value &gt; 10% within 30 days prior to the transplant. 3. Subjects who have received a multiorgan transplant. 4. Subjects who are who are positive for hepatitis C, hepatitis B surface antigen or HIV. 5. Subjects who have received an investigational drug within 6 weeks of study entry. 6. Subjects who have a previous history of, or who currently have, malignancies and/or lymphoma. 7. Subjects who have received corticosteroids within three months of transplantation. 8. Subjects who are 3rd transplant recipients. 9. Female subjects who are pregnant or lactating. Fertile female subjects who are sexually active must agree to use an acceptable method of birth control during the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>living or deceased donor renal transplant recipient</keyword>
</DOC>